Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin's lymphoma: a first-in-human phase I study

BACKGROUND: Thus far, all approved chimeric antigen receptor (CAR)-T products are manufactured using modified viruses, which increases the risk of tumorigenesis, costs and production time. We aimed to evaluate the safety and efficacy of a kind of virus-free CAR-T cells (PD1-19bbz), in which an anti-...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Yongxian, Zu, Cheng, Zhang, Mingming, Wei, Guoqing, Li, Wei, Fu, Shan, Hong, Ruimin, Zhou, Linghui, Wu, Wenjun, Cui, Jiazhen, Wang, Dongrui, Du, Bing, Liu, Mingyao, Zhang, Jiqin, Huang, He
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209187/
https://www.ncbi.nlm.nih.gov/pubmed/37251628
http://dx.doi.org/10.1016/j.eclinm.2023.102010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209187/
https://www.ncbi.nlm.nih.gov/pubmed/37251628
http://dx.doi.org/10.1016/j.eclinm.2023.102010

Ejemplares similares